T-cell receptor excision circles (TRECs) and κ-deleting recombination excision circles (KRECs) are recently used for detection of T or B cell lymphopenia in neonates based on region-specific cutoff levels. Here, we report cutoffs for TREC and KREC copies useful for newborn screening and/or diagnosis of primary immunodeficiency diseases (PID) in Iran. DNA was extracted from a single 3.2 mm punch of dried blood spots collected from 2160 anonymized newborns referred to two major referral health centres between 2014 and 2016. For refinement of the cutoffs, 51 patients with a definite diagnosis of severe combined immunodeficiency, X-linked agammaglobulinaemia and combined immunodeficiency, including ataxia telangiectasia, human phosphoglucomutase 3 and Janus kinase-3 deficiency, as well as 47 healthy controls were included. Samples from patients with an X-linked hyper-IgM-syndrome, Wiskott-Aldrich syndrome and DNA ligase 4 deficiency were considered as disease controls. Triplex-quantitative real-time PCR was used. Cutoffs were calculated as TRECs < 11 and KRECs < 6 copies with an ACTB > 700 copies with sensitivity of 100% for TREC and 97% for KREC. Among thirty anonymized newborn samples (1.5%) with abnormal results for TREC and/or KREC, only twenty-one available cases were retested and shown to be in the normal range except for three samples (0.15%). All of the patients with a definitive diagnosis were correctly identified based on our established TREC/KREC copy numbers. Determining cutoffs for TREC/
| INTRODUCTION
Primary immunodeficiency diseases (PID) is a group of heterogeneous genetic disorders affecting cellular and/or humoral compartments of the immune system. [1] [2] [3] To date, more than 300 types of PID have been reported, however a large number of defects are still to be expected. 1 Recent evidence suggests that the prevalence of undiagnosed PID is far higher than previously reported, and is estimated to be approximately 1 in 1200 persons in the United States. 4 The incidence is increased in Iran because of a high rate of consanguineous marriages, contributing to autosomal-recessive inheritance modes commonly seen in PID. 5 Severe combined immunodeficiency (SCID) is caused by defects in several genes relevant for the development of T and B lymphocytes. [6] [7] [8] In addition to T cell defects as a hallmark of SCID, B cell defects can also be found, either due to defective B cell developmental process or a lack of T cell help. 6 These deficiencies manifest by immune response dysregulation, resulting in serious infections and an increased risk of malignancies. 9 Due to transferred maternal antibodies, protecting infants in the first few months of life, patients with profound T cell deficiencies such as SCID are frequently not identified until later in infancy when they present with severe infections and other complications. 10, 11 Therefore, early diagnosis of SCID patients before the onset of infections enables early institution of life-saving interventions, including infection-preventative modalities and definitive treatment with gene therapy or hematopoietic stem cell transplantation (HSCT). Evidence suggests that outcomes are greatly improved if HSCT takes place prior to the age of 3-3.5 months, when the infectious burden is low. 6, 12 Apart from the newborn screening for congenital immune deficiencies, the TREC/ KREC assay an also be applied for follow-up the hematopoietic stem cell transplantation or for monitoring of the treatment success in acquired immune deficiencies and autoimmune diseases. 13 Recent methods have been developed for newborn screening by identifying T and/or B cell deficiencies. By measuring the copy numbers of T cell receptor excision circles (TRECs) and κ-deleting excision circles (KRECs), it is possible to identify T and B lymphopenia related disorders (including SCID, X-linked agammaglobulinemia (XLA) and ataxia telangiectasia (AT)). TREC and KREC, DNA biomarkers of the natural development of T and B lymphocytes respectively, can be easily extracted from dried blood spots (DBS) on Guthrie cards and measured by real-time quantitative PCR. 14, 15 Since these two extra-chromosomal or episomal DNA circles do not replicate during mitosis, precise assessment of copy numbers is a reliable tool to quantitatively evaluate TCR/BCR rearrangements during T/ B cell generation in the thymus and bone marrow. 10, 11, 16 Due to variability of TREC/KREC cutoffs obtained between different countries and ethnicities, they need to be determined in each region or country individually.
14 The aim of this study was to identify the TREC/KREC copy number cutoffs based on the analysis of DBS samples of healthy Iranian newborns as well as samples from a series of PID patients with a definitive diagnosis. Subsequently, the screening of a cohort of 2160 Iranian newborns was performed using these cutoff values.
| MATERIALS AND METHODS

| Sources of patient samples and newborn
Guthrie cards
In order to evaluate the possible range of TREC and KREC copy values, we initially investigated 47 healthy full-term (>37 weeks gestation, birth weight of >2500 g) non-anonymized newborns (identified in the Neonatal Department, Valiasr Hospital, Tehran University of Medical Science (TUMS), Tehran, Iran) and fifty-one EDTA-blood samples of patients with a definitive diagnosis of SCID (n = 31), XLA (n = 9) and combined immunodeficiency diseases (CID) 17 including AT (n = 9), Human phosphoglucomutase 3(PGM3; n = 1) and Janus kinase-3 (JAK3;n = 1) deficiency. One JAK3 deficient patient was included in CID group due to clinical manifestation and finding a hypomorphic mutation. Thereafter, to establish and verify the accuracy, specificity and sensitivity of the cutoff values, we included 2160 anonymized newborn heel stick blood samples collected onto GE 903 Guthrie cards (GE Healthcare Life Sciences Corp, Marlborough, MA, USA) at two major referral health centres for newborn screening, covering all four main regions in Tehran, Iran (Homayoonzahra and Shahid Jafari health centres, Shahid Beheshti University of Medical Science). DBS samples were collected 3 to 5 days after birth. After drying the samples at room temperature, Guthrie cards were kept at 4°C for 0-48 hours until assessment. We also used 11 DBS samples from CID patients including x-linked hyper-IgM-syndrome (x-linked HIgM; n = 1; 24 years; male), DNA ligase 4 deficiency (LIG4; n = 1; 7 years; female) and Wiskott-Aldrich syndrome (WAS; n = 9; age range 1-17 years) as internal disease controls. All of these patients had been referred to the Immunology, Asthma and Allergy Research Institute (IAARI), TUMS, Tehran, Iran between 2011 and 2015 and their blood samples had been stored in the IAARI's DNA and blood bank frozen at −80°C. Fifty microliters of each EDTA-blood sample was transferred onto a Guthrie card and a single 3.2 mm DBS from each sample was punched into one well of a 96-well filter plate. All DBS samples were assessed using a preliminary version of a TREC/ KREC screening kit (now distributed by ImmunolVD, Sweden, Stockholm). Demographic and clinical data, as well as laboratory findings including immunophenotyping of T, B and NK cells, were collected from the IAARI PID Registry.
2.2 | DNA extraction from dried blood spot punches DNA was extracted from 3.2 mm punched DBS samples. Briefly, following incubation with a rinse solution in the filter plate and subsequent centrifugations, the punches were transferred to a 96-well elution plate containing DNA elution solution and were heat-eluted using a Gradient PalmCycler CG1-96 (Corbett Research, Sydney, Australia) at 99°C for 30 minutes. Extracted DNA was transferred by centrifugation to a qPCR plate for the real-time PCR process. The β-actin (ACTB) copy number was considered as an internal control for confirming the quality of DNA extracted from DBS punches and the real-time PCR process. DBS samples with an ACTB level higher than 700 copies/3.2 mm DBS were considered conclusive samples. Some samples were lost due to liquid evaporation during the heat-elution step at 99°C, which could be the result of proximity to boiling temperature or a higher than expected temperature at some points on the thermocycler hot plate. The manufacturer informed us, that these issues have been solved in the TREC/KREC SCREEN-ID kit version available as of 2017 and the failure is reduced to 0-1 wells of a 96-well elution plated. We instead tried to fix the problem using covering tools for elution plates including cap strips, aluminum seal or ABI silicone mat, and also by changing to a thermocycler with a temperature-adjustable lid as recommended by the supplier. As a result, the sample failure was reduced to 4-7 wells of a 96-well elution plate. The standard curve was drawn according to the standard plasmids provided in the kits containing 10-100 000 copies of TREC and KREC and 200-2 000 000 copies for ACTB.
| Triplex real-time PCR
TREC-KREC-ACTB triplex real-time quantitative PCR (RT-qPCR) was carried out in a final volume of 20 μL using hydrolysis probe chemistry on a 7500 ABI Real Time PCR system (Applied Biosystems, California, USA). Thermal cycler conditions were as follows: initial denaturation for 2 minutes at 50°C, a heating cycle of 10 minutes at 95°C, followed by 45 cycles of 15 seconds at 95°C and 30 seconds at 60°C, according to manufacturer's instructions. Cycle threshold for TREC, KREC and ACTB was automatically fixed on the amplification curve during the exponential phase. TREC/KREC quantification was performed using the standard curve method with identical slopes and R 2 values ˃0.97. Standard curves were established according to the serial dilution of defined copy numbers of TREC, KREC and ACTB circular plasmids distributed in qPCR plates. Three different control Guthrie cards (provided in the kit) were also used as follows: absent TREC (T cell depleted blood sample), absent KREC (B cell depleted blood sample) and absent TREC and KREC (T and B cell depleted blood sample). Finally, TREC/KREC levels were determined per 3.2 mm-punch of Guthrie cards. Forward and reverse primers were designed by ImmunolVD.
| Sanger sequencing of PID patients
DNA was extracted from patients' blood samples in order to evaluate the underlying defects of selected genes for PID patients including RAG1, RAG2, IL2Rγ, IL-7Rα, or ADA, BTK, CD40L and WASP. The genes were amplified by polymerase chain reaction (PCR) (ASTEC thermo cycler, Fukuoka, Japan) and detected by a gel electrophoresis documentation system (BIO RAD, California, USA). The PCR products were subsequently outsourced for Sanger sequencing analysis (Macrogen, Seoul, South Korea) to determine the genetic defects. Genetic analysis of all patients was performed retrospectively. A definitive diagnosis was made by cumulating data of immunological assessments and molecular analyses.
| Data analysis
Statistical analyses were performed using Excel 2013 (Microsoft office, USA) and SPSS Software version 16.0 (Microsoft Corporation, Chicago, Illinois, USA). The scatter plot and receiver operating characteristic (ROC) curves were also created using GRAPHPAD PRISM software version 7 (GraphPad software, San Diego, CA, USA). Quantitative variables were analysed using the Kolmogorov-Smirnov test for normal distribution and expressed as mean ± standard deviation and median and lower (Q1) and upper quartile (Q3). TREC and KREC copy number were dichotomized using ROC curve analysis. 18 A 95% confidence interval was computed for ROC curves. A P value of <0.05 was considered statistically significant.
| Ethics
This study was approved by the ethics committee of TUMS (412/P/239). Samples were assessed after obtaining informed consent from the participants or their guardians.
| RESULTS
| Cutoff values for identification of SCID,
XLA and some cases of CID
To determine the cutoff values, ROC curves for TREC/ KREC copy numbers were drawn. On the basis of the TREC/KREC copy numbers determined for the known SCID, XLA and CID patients and anonymized newborn samples, diagnostically relevant cutoff values were set at 11 copies/3.2 mm DBS for TRECs and 6 copies/3.2 mm DBS for KRECs, regionally. Cutoff values were estimated to have a sensitivity of 100% for TREC and 97% for KREC at the expense of the specificity in the detection of SCID, XLA and CID cases (AT, PGM3 and JAK3 deficiency) (Figure 1 and 2 ). The mean, median, maximum and minimum values were calculated for the TREC, KREC and ACTB copy numbers for 1980 anonymized newborn samples, as shown in Table 1 . As shown in Table 3 , the TREC copy number was below 1 or zero in all 31 SCID patients and two cases with PGM3 and JAK3 deficiency. Data obtained from this study showed a low or zero copy numbers of KREC in autosomal recessive SCID (AR-SCID) patients. However, in 3 AR-SCID patients with IL-7Rα and two x-linked SCID patients (IL-2Rγ) the KREC copy numbers were higher than our cutoff values, thereby resembling the genetically determined immunophenotype. Moreover, despite having the phenotype of T − B + SCID in three patients (#6, 29, 31) with normal KREC copy numbers, we could not find any mutations for them in routinely tested genes in our lab, suggesting other genetic traits. In the case of KREC copy numbers, the JAK3 deficient patient had normal levels of KREC while the PGM3 deficient patient showed a copy number of KREC just below the cutoff. Moreover, all 9 AT patients showed a notable reduction of both TREC and KREC. Nine XLA patients were identified by low KREC copy numbers, but normal TREC values (as shown in Table 3 and Figure 2 ).
| Positive and negative controls
Applying our derived cutoff values, TREC/KREC levels from control samples, including patients with a known diagnosis of WAS, X-linked-HIgM syndrome (CD40L deficient) and LIG4deficiency were assessed. All WAS patients except for two cases (age: 1 and 7 years, both male) had normal levels of TRECs and KRECs. The two WAS cases fell in the TREC (−) KREC (+) region of the TREC/ KREC graph that was drawn due to the normal newborn results. In contrast to X-linked HIgM syndrome (CD40L deficiency) with TREC+KREC+, the LIG4 deficient patient indicated very low copy numbers of both TRECs and KRECs (TREC 
| Diagnostic procedures and sample quality in Guthrie card analysis
As shown in Figure 3 , out of 2160 neonate samples, 168 cases (7.8%) showed low copy numbers for ACTB (inconclusive results) and were excluded from the study, as re-testing of a second sample was not possible logistically. Thirty cases of 1992 samples with ACTB>700 (1.5%) were found to have low copy numbers of TREC and/or KREC in the context of an adequate ACTB level and were referred to as "abnormal or positive" samples. However, only 21 (1%) samples could be re-tested due to lack of availability of the remaining samples for further evaluation. A new punch of old Guthrie cards was taken (11 DBS with low TREC numbers, nine samples with low KREC numbers, and one sample in which both were low) and was analyzed. We finally could find abnormal results for three retested samples (0.15%) and
F I G U R E 1 ROC curve analysis of TREC (A) and KREC (B)
copy numbers. Red curves and black lines represent ROC curves and reference line, respectively nine non-repeated samples (0.45%) ( Table 2) . One thousand, nine hundred and eighty cases remained and were used to determine the cutoff values.
| DISCUSSION
In the present study, for the first time we determined the cutoff values for TREC and KREC copy numbers in an Iranian neonatal cohort, which would enable the accurate identification of patients with T and B cell lymphopenia in SCID, XLA and AT at birth. These levels provide threshold values which can be applied both to newborn screening for PID and early diagnosis of infants with a family history of PID in Iran. This represents valuable information in the context of the Iranian population, as thresholds have been shown to differ in between various countries where screening studies had been undertaken. 14, 19 For instance, proposed diagnostic cutoffs for populations in Germany and Sweden were determined as 15 TRECs/μL and 10 KRECs/ μL based on a previous evaluation in 2560 newborns, and was later modified to 8 TRECs/μL and 6 KRECs/μL, respectively, subsequent to more sample evaluations. 15, 20 In fact, different cutoffs have been reported based on population, sample size, laboratory method and the related algorithms utilized in particular screening programs. Therefore, a wide range of TREC cutoffs, ranging from 7 to 252 TRECs/μL can be found in different reports. 21 We analysed TREC/KREC levels in patients with a known diagnosis of PID including SCID, XLA AT as well as PGM3 and JAK3 deficiency. There are many gene mutations involved in T cell differentiation in the thymus, including X-linked (IL-2Rγ) and auotosomal recessive (IL7Rα, ADA, JAK3, RAG1, RAG2, CD45 and Artemis). These defects can block the T cell development resulting in T cell lymphopenia or, in its most severe form, SCID. Autosomal recessive gene defects can also affect B cell development and lead to a phenotype of simultaneous impaired generation of T and B cells in SCID patients. 22 As expected, all SCID patients with different phenotypes (lacking one or more of T, B or NK cell compartments) had no detectable TREC copies, but variable numbers of KREC copies, which is in accordance with their phenotype. Autosomal recessive SCID patients showed low or absent KREC copies except for patients with IL-7Rα. However, X-linked SCID patients showed normal level of KREC and zero copies of TREC. As indicated in the results, despite evaluation of five genes (indicated in the method section) we could not find any mutation in three patients (#6, 29, 31) with positive a KREC value and immunophenotyping F I G U R E 2 TREC and KREC copy numbers from anonymized newborn DBS samples (n = 1962) (grey circles), retested samples (n = 21) (black squares) and patients with a known diagnosis of severe combined immunodeficiency (SCID; n = 31) (red stars), X-linked agammaglobulinemia (XLA; n = 9) (blue triangles), ataxia telangiectasia (AT; n = 9) (pink hexagons), Human phosphoglucomutase 3 deficiency (PGM3; n = 1) (green diamonds), Janus kinase-3 deficiency (JAK3; n = 1) (blue diamonds), DNA ligase 4 deficiency (LIG4; n = 1) (green triangles), x-linked hyper-IgM-syndrome (HIgM; n = 1) (Blue circles), Wiskott-Aldrich syndrome (WAS; n = 9) (brown stars) and healthy controls (n = 47) (open circles). Dotted lines represent cutoff values for TREC and KREC levels, respectively, (given as copies/3.2 mm DBS). The scatter plot was plotted using GRAPHPAD PRISM software version 7 (GraphPad software, USA). Red star: some stars have been overlapped according to the same results This is the first time where TREC/KREC copy numbers have been determined in a patient with PGM3 deficiency. In the current study, low levels of these parameters were in accordance to the mutation indicated for PGM3 gene leading to the impairment of B and T cell production 23 as well as the results of immunophenotyping (Table 3 ). According to previous studies, 24 gene alterations affecting the JAK3 signalling pathway, which is necessary for lymphoid cell development, creates a phenotype of T − B + NK − SCID. In this type of SCID, despite a normal quantity of B cells, there is a defect in activation and differentiation of these cells. 25, 26 In the case of the JAK3 patient, we found low copies of TREC but normal values of KREC which were not wellmatched with the normal percentages of T, B and NK cells and normal function of lymphocytes using a lymphocyte transformation test (data not shown). However, our results were in concordance to the reports of Borte et al and Puck et al indicating the copy numbers of TRECs below the cutoff values. 15, 27 Unfortunately, BCG vaccination was carried out in 21 out of our 33 SCID patients (64%) which resulted incomplicated problems in 5 patients. 28 To avoid the postvaccination complications and also timely finding of appropriate donors, it is highly recommended to run a national screening program to identify suspected patients especially in families without a positive history of PIDs. Regardless of the patients age, B and T cell immunodeficiency is a hallmark of AT, along with chromosome instability and neurodegeneration. 15, 29, 30 In this study, we observed that patients with AT generally had very low numbers of both TRECs and KRECs (with the exception of one female patient (# 12) with a normal KREC level), although there was no obvious correlation with the percentages of T and B cells (n = 3). Mutation in the Bruton tyrosine kinase (BTK) gene result in an absence of B cells 31 and this was reflected in our XLA patients who demonstrated an absence of or extremely low level of KREC, which is consistent with previous studies. 15, 16, 32 We also evaluated TREC/KREC levels in several patients with known PID, including WAS, X-linked HIgM and LIG4 deficiency. Seven WAS patients had levels above cutoff for both markers, aligning them with values obtained from healthy controls and two WAS patients had low TREC copy numbers. 15, 33 As shown in previous studies, normal copy numbers of TREC and KREC in patients with CD40 ligand deficiency was consistent with non-involvement of CD40 ligand in the cell differentiation process. 15, 34, 35 During this study, we evaluated a 7-year old PID patient with a clinical and laboratory manifestation of an X-linked HIGMlike syndrome. In addition to low copy numbers of TREC and KREC, which was in accordance to a recent report on LIG4 deficiency, 36 we found a heterozygous recessive mutation in the LIG4 gene subsequent to the genetic analysis of the patient. Our results were in contrast to a report of Puck and et al indicating a normal value of B and NK cells in one patient with of LIG4 deficiency 37, 38 ; while they could reflect involvement of LIG4 gene in B cell development. Similar to AT and JAK3 cases, we did not observe any correlation between TREC/KREC copy numbers and immunophenotyping results of our LIG4 deficient patient. It illustrates that by sole analysis of CD markers; it might not be possible to diagnose these complicated PID patients. Therefore, molecular TREC/KREC testing should be considered as a powerful tool to initially screen the patient with a clinical appearance of PID and paradoxical laboratory results. Regarding the age of the LIG4 deficient patient, it should be recapitulated that age is an important determining factor in interpreting TREC/KREC values. It is generally assumed that the thymic function as well as T cell proliferation change due to thymic involution. 39 Moreover, TREC and KREC molecules are unable to duplicate during mitosis. Therefore, their levels decrease after each peripheral cell division in healthy individuals and patients result in a gradual diminished level of these two parameters over their life span. [39] [40] [41] Hence, calculating TREC/KREC thresholds for different age ranges would be helpful in clinical interpretation of these results outside of the neonatal period. Consequently, we determined the reference values of both two molecules for different Iranian age groups. 42 In the case of the LIG4 patient, KREC level was very low related to norm-referenced group. Two WAS patients with low copy numbers of TREC also fell out of normal region. As shown in Figure 3 , during the evaluation of 2160 anonymized newborns, DBS samples with an ACTB level lower than 700 copies/3.2 mm DBS and concurrent reduction of TREC and KREC were considered as "inconclusive." This could be accounted for technical factors, including evaporation during the PCR process or an insufficient amount of blood and DNA on the Guthrie filter paper. It was not possible for us to follow these three retested patients as well as false positive cases (as shown in Table 2 ), due to the lack of access to the infants and the possibility to obtain new samples and collect demographic, clinical and laboratory data of these 21 cases. Therefore, we can consider them as false positive results or they may in fact be immunodeficient patients. Some studies indicated that low copy numbers of TREC/KREC might relate to some factors including drug use during pregnancy or premature birth. 29, 43 
T A B L E 1 Descriptive statistics for TREC, KREC and ACTB copy numbers from 1980 anonymized newborn DBS samples
Median (Q1, Q3) (copies/3.2 mm DBS)
Minimum
